Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders
Journal of Ocular Pharmacology and Therapeutics · 01.04.2023 · 39 (3) · 191-206
DOI: 10.1089/jop.2022.0174 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, online erschienen am 04.04.2023. Verfasst von Steven E Wilson. Beteiligte Einrichtung: The Cole Eye Institute, The Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Corneal Dystrophies, Hereditary, Eye Diseases, Corneal Injuries. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS.
Abstract (Originalsprache)
Losartan is an angiotensin II receptor blocker (ARB) that impedes transforming growth factor (TGF) beta signaling by inhibiting activation of signal transduction molecule extracellular signal-regulated kinase (ERK). Studies supported the efficacy of topical losartan in decreasing scarring fibrosis after rabbit Descemetorhexis, alkali burn, and photorefractive keratectomy injuries, and in case reports of humans with scarring fibrosis after surgical complications. Clinical studies are needed to explore the efficacy and safety of topical losartan in the prevention and treatment of corneal scarring fibrosis, and other eye diseases and disorders where TGF beta has a role in pathophysiology. These include scarring fibrosis associated with corneal trauma, chemical burns, infections, surgical complications, and persistent epithelial defects, as well as conjunctival fibrotic diseases, such as ocular cicatricial pemphigoid and Stevens–Johnson syndrome. Research is also needed to explore the efficacy and safety of topical losartan for hypothesized treatment of transforming growth factor beta-induced ( TGFBI )-related corneal dystrophies (Reis–Bu¨cklers corneal dystrophy, lattice corneal dystrophy type 1, and granular corneal dystrophies type 1 and type 2) where deposited mutant protein expression is modulated by TGF beta. Investigations could also explore the efficacy and safety of topical losartan treatments to reduce conjunctival bleb scarring and shunt encapsulation following glaucoma surgical procedures. Losartan and sustained release drug delivery devices could be efficacious in treating intraocular fibrotic diseases. Dosing suggestions and precautions that should be considered in trials of losartan are detailed. Losartan, as an adjuvant to current treatments, has the potential to augment pharmacological therapeutics for many ocular diseases and disorders where TGF beta plays a central role in pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Cole Eye Institute, The Cleveland Clinic, Cleveland, Ohio, USA.
Förderung
- NEI NIH HHS
Zitieren
APA
Wilson, S. E. (2023). Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders. Journal of Ocular Pharmacology and Therapeutics, 39(3), 191-206. https://doi.org/10.1089/jop.2022.0174
Vancouver
Wilson SE. Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders. Journal of Ocular Pharmacology and Therapeutics. 2023;39(3):191-206. doi:10.1089/jop.2022.0174
BibTeX
@article{Wilson2023,
author = {Wilson, Steven E},
title = {Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders},
journal = {Journal of Ocular Pharmacology and Therapeutics},
year = {2023},
volume = {39},
number = {3},
pages = {191--206},
doi = {10.1089/jop.2022.0174}
}
EUVIMED